Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.

Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D.

Haematologica. 2019 Mar;104(3):564-575. doi: 10.3324/haematol.2018.196725. Epub 2018 Oct 11.

2.

Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.

Aldinucci D, Casagrande N.

Int J Mol Sci. 2018 May 16;19(5). pii: E1477. doi: 10.3390/ijms19051477. Review.

3.

Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media.

Agostini F, Rossi FM, Aldinucci D, Battiston M, Lombardi E, Zanolin S, Massarut S, Parodi PC, Da Ponte A, Tessitori G, Pivetta B, Durante C, Mazzucato M.

Stem Cell Res Ther. 2018 May 11;9(1):130. doi: 10.1186/s13287-018-0886-1.

4.

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29.

5.

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.

Borghese C, Casagrande N, Pivetta E, Colombatti A, Boccellino M, Amler E, Normanno N, Caraglia M, De Rosa G, Aldinucci D.

Oncotarget. 2017 Jun 27;8(26):42926-42938. doi: 10.18632/oncotarget.17216.

6.

New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.

Altaf M, Monim-Ul-Mehboob M, Kawde AN, Corona G, Larcher R, Ogasawara M, Casagrande N, Celegato M, Borghese C, Siddik ZH, Aldinucci D, Isab AA.

Oncotarget. 2017 Jan 3;8(1):490-505. doi: 10.18632/oncotarget.13448.

7.

Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2 -activated platelet concentrates promoted expansion of mesenchymal stromal cells.

Borghese C, Agostini F, Durante C, Colombatti A, Mazzucato M, Aldinucci D.

Vox Sang. 2016 Aug;111(2):197-205. doi: 10.1111/vox.12405. Epub 2016 Apr 14.

PMID:
27077937
8.

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.

Aldinucci D, Celegato M, Casagrande N.

Cancer Lett. 2016 Sep 28;380(1):243-52. doi: 10.1016/j.canlet.2015.10.007. Epub 2015 Oct 23. Review.

PMID:
26474544
9.

Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Celegato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, Spina M, Colombatti A, Aldinucci D.

Blood. 2015 Sep 10;126(11):1394-7. doi: 10.1182/blood-2015-07-660365. Epub 2015 Jul 30. No abstract available.

10.

Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Clin Cancer Res. 2014 Nov 1;20(21):5496-506. doi: 10.1158/1078-0432.CCR-14-0713. Epub 2014 Sep 17.

11.

Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts.

Celegato M, Fregona D, Mongiat M, Ronconi L, Borghese C, Canzonieri V, Casagrande N, Nardon C, Colombatti A, Aldinucci D.

Future Med Chem. 2014 Jul;6(11):1249-63. doi: 10.4155/fmc.14.81.

PMID:
25162999
12.

The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.

Celegato M, Borghese C, Umezawa K, Casagrande N, Colombatti A, Carbone A, Aldinucci D.

Cancer Lett. 2014 Jul 10;349(1):26-34. doi: 10.1016/j.canlet.2014.03.030. Epub 2014 Apr 2.

PMID:
24704296
13.

The inflammatory chemokine CCL5 and cancer progression.

Aldinucci D, Colombatti A.

Mediators Inflamm. 2014;2014:292376. doi: 10.1155/2014/292376. Epub 2014 Jan 2. Review.

14.

Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.

Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Gynecol Oncol. 2013 Dec;131(3):744-52. doi: 10.1016/j.ygyno.2013.08.041. Epub 2013 Sep 10.

PMID:
24029417
15.

Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.

Celegato M, Borghese C, Casagrande N, Carbone A, Colombatti A, Aldinucci D.

Leuk Lymphoma. 2014 Jan;55(1):149-59. doi: 10.3109/10428194.2013.800196. Epub 2013 Jun 12.

PMID:
23647062
16.

Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.

Borghese C, Cattaruzza L, Pivetta E, Normanno N, De Luca A, Mazzucato M, Celegato M, Colombatti A, Aldinucci D.

J Cell Biochem. 2013 May;114(5):1135-44. doi: 10.1002/jcb.24456.

PMID:
23192362
17.

Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy.

Kouodom MN, Boscutti G, Celegato M, Crisma M, Sitran S, Aldinucci D, Formaggio F, Ronconi L, Fregona D.

J Inorg Biochem. 2012 Dec;117:248-60. doi: 10.1016/j.jinorgbio.2012.07.001. Epub 2012 Jul 11.

PMID:
22877925
18.

Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics.

Kouodom MN, Ronconi L, Celegato M, Nardon C, Marchiò L, Dou QP, Aldinucci D, Formaggio F, Fregona D.

J Med Chem. 2012 Mar 8;55(5):2212-26. doi: 10.1021/jm201480u. Epub 2012 Feb 23.

PMID:
22309237
19.

The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment.

Aldinucci D, Gloghini A, Pinto A, Colombatti A, Carbone A.

Leuk Lymphoma. 2012 Feb;53(2):195-201. doi: 10.3109/10428194.2011.605190. Epub 2011 Aug 24. Review.

PMID:
21756027
20.

Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells.

De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, Pinto A, Normanno N.

J Cell Physiol. 2011 Aug;226(8):2131-8. doi: 10.1002/jcp.22548.

PMID:
21520065
21.

IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.

Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A.

Br J Haematol. 2011 Jan;152(2):182-90. doi: 10.1111/j.1365-2141.2010.08497.x. Epub 2010 Nov 28.

PMID:
21114485
22.

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A.

J Pathol. 2010 Jul;221(3):248-63. doi: 10.1002/path.2711. Review.

PMID:
20527019
23.

Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts.

Cattaruzza L, Fregona D, Mongiat M, Ronconi L, Fassina A, Colombatti A, Aldinucci D.

Int J Cancer. 2011 Jan 1;128(1):206-15. doi: 10.1002/ijc.25311.

24.

Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes.

Ronconi L, Aldinucci D, Dou QP, Fregona D.

Anticancer Agents Med Chem. 2010 May;10(4):283-92. Review.

PMID:
20184554
25.

Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond.

Aldinucci D, Pinto A, Gloghini A, Carbone A.

Blood. 2010 Jan 21;115(3):746-7; author reply 748. doi: 10.1182/blood-2009-10-247809. No abstract available.

26.

IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma.

Aldinucci D, Rapana' B, Olivo K, Lorenzon D, Gloghini A, Colombatti A, Carbone A.

Br J Haematol. 2010 Jan;148(1):115-8. doi: 10.1111/j.1365-2141.2009.07945.x. Epub 2009 Oct 11.

PMID:
19821826
27.

Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma.

Cattaruzza L, Gloghini A, Olivo K, Di Francia R, Lorenzon D, De Filippi R, Carbone A, Colombatti A, Pinto A, Aldinucci D.

Int J Cancer. 2009 Sep 1;125(5):1092-101. doi: 10.1002/ijc.24389.

28.

Antiproliferative and apoptotic effects of two new Pd(II) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro.

Aldinucci D, Cattaruzza L, Lorenzon D, Giovagnini L, Fregona D, Colombatti A.

Oncol Res. 2008;17(3):103-13.

PMID:
18669162
29.

Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.

Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, Colombatti A.

Int J Cancer. 2008 Feb 15;122(4):769-76.

30.

The role of the EGFR signaling in tumor microenvironment.

De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N.

J Cell Physiol. 2008 Mar;214(3):559-67. Review.

PMID:
17894407
31.

Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro.

Aldinucci D, Lorenzon D, Stefani L, Giovagnini L, Colombatti A, Fregona D.

Anticancer Drugs. 2007 Mar;18(3):323-32.

PMID:
17264766
32.

Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis.

Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A, De Filippi R, Pinto A.

Endocr Relat Cancer. 2005 Jun;12(2):471-82.

PMID:
15947117
33.

Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas.

Corazzelli G, Capobianco G, Russo F, Frigeri F, Aldinucci D, Pinto A.

Haematologica. 2005 Mar;90(3):ECR14.

34.

Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes.

Giovagnini L, Ronconi L, Aldinucci D, Lorenzon D, Sitran S, Fregona D.

J Med Chem. 2005 Mar 10;48(5):1588-95.

PMID:
15743200
35.

The role of interleukin-3 in classical Hodgkin's disease.

Aldinucci D, Olivo K, Lorenzon D, Poletto D, Gloghini A, Carbone A, Pinto A.

Leuk Lymphoma. 2005 Mar;46(3):303-11. Review.

PMID:
15621820
36.

Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells.

Aldinucci D, Lorenzon D, Olivo K, Rapanà B, Gattei V.

Leuk Lymphoma. 2004 Sep;45(9):1731-9. Review.

PMID:
15223630
37.

CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.

Aldinucci D, Poletto D, Lorenzon D, Nanni P, Degan M, Olivo K, Rapanà B, Pinto A, Gattei V.

Clin Cancer Res. 2004 Jan 15;10(2):508-20.

38.

The role of interleukin-3 and stem cell factor in classical Hodgkin disease.

Aldinucci D, Gattei V.

Blood. 2003 Jan 1;101(1):376-7. No abstract available.

39.

CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts.

Aldinucci D, Poletto D, Nanni P, Degan M, Rupolo M, Pinto A, Gattei V.

Exp Hematol. 2002 Nov;30(11):1283-92.

PMID:
12423681
40.

Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor.

Aldinucci D, Poletto D, Nanni P, Degan M, Gloghini A, Di Francia R, Russo S, Carbone A, Pinto A, Gattei V.

Br J Haematol. 2002 Sep;118(4):1055-64.

PMID:
12199785
41.

A novel bcl-1/JH breakpoint from a patient affected by mantle cell lymphoma extends the major translocation cluster.

Degan M, Doliana R, Gloghini A, Di Francia R, Aldinucci D, Mazzocut-Zecchin L, Colombatti A, Attadia V, Carbone A, Gattei V.

J Pathol. 2002 Jun;197(2):256-63.

PMID:
12015751
42.

Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease.

Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G.

Br J Haematol. 2002 May;117(2):366-72.

PMID:
11972519
43.

Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells.

Rossi FM, Degan M, Mazzocco FT, Di Francia R, Aldinucci D, Poletto D, Vellenga E, Pinto A, Gattei V.

Br J Haematol. 2002 Apr;117(1):59-69.

PMID:
11918534
44.

Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells.

Aldinucci D, Poletto D, Gloghini A, Nanni P, Degan M, Perin T, Ceolin P, Rossi FM, Gattei V, Carbone A, Pinto A.

Am J Pathol. 2002 Feb;160(2):585-96.

45.

CD30L up-regulates CD30 and IL-4 expression by T cells.

Rossi FM, Degan M, Mazzocut-Zecchin L, Di Francia R, Aldinucci D, Pinto A, Gattei V.

FEBS Lett. 2001 Nov 23;508(3):418-22.

46.

In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies.

Aldinucci D, Poletto D, Zagonel V, Rupolo M, Degan M, Nanni P, Gattei V, Pinto A.

Br J Haematol. 2000 Jul;110(1):188-96.

PMID:
10930997
47.

CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation.

Gattei V, Degan M, Rossi FM, de Iuliis A, Mazzocco FT, Serraino D, Zagonel V, Aldinucci D, Pinto A.

Leuk Lymphoma. 1999 Sep;35(1-2):21-35. Review.

PMID:
10512160
48.

The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation.

Gattei V, Degan M, Rossi FM, De Iuliis A, Mazzocco FT, Cesa E, Aldinucci D, Zagonel V, Pinto A.

Br J Haematol. 1999 Apr;105(1):225-40.

PMID:
10233387
49.

Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells.

Gattei V, Godeas C, Degan M, Rossi FM, Aldinucci D, Pinto A.

Br J Haematol. 1999 Jan;104(1):152-62.

PMID:
10027728
50.

Differential expression of the RET gene in human acute myeloid leukemia.

Gattei V, Degan M, Aldinucci D, De Iuliis A, Rossi FM, Mazzocco FT, Rupolo M, Zagonel V, Pinto A.

Ann Hematol. 1998 Nov;77(5):207-10.

PMID:
9858145

Supplemental Content

Loading ...
Support Center